Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.
Hendrikse CSE, Theelen PMM, van der Ploeg P, Westgeest HM, Boere IA, Thijs AMJ, Ottevanger PB, van de Stolpe A, Lambrechts S, Bekkers RLM, Piek JMJ. Hendrikse CSE, et al. Among authors: westgeest hm. Gynecol Oncol. 2023 Apr;171:83-94. doi: 10.1016/j.ygyno.2023.01.038. Epub 2023 Feb 24. Gynecol Oncol. 2023. PMID: 36841040 Free article. Review.
Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer.
Mendelaar PAJ, Robbrecht DGJ, Rijnders M, de Wit R, de Weerd V, Deger T, Westgeest HM, Aarts MJB, Voortman J, Martens JWM, van der Veldt AAM, Nakauma-González JA, Wilting SM, Lolkema M. Mendelaar PAJ, et al. Among authors: westgeest hm. Mol Oncol. 2022 May;16(10):2086-2097. doi: 10.1002/1878-0261.13196. Epub 2022 Mar 17. Mol Oncol. 2022. PMID: 35181986 Free PMC article.
Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry.
Kuppen MCP, Westgeest HM, van den Eertwegh AJM, van Moorselaar RJA, van Oort IM, Coenen JLLM, van den Bergh ACMF, Mehra N, Somford DM, Bergman AM, Ten Bokkel Huinink D, Fossion L, Geenen MM, Hendriks MP, van de Luijtgaarden ACM, Polee MB, Weijl NI, van de Wouw AJ, de Wit R, Uyl-de Groot CA, Gerritsen WR. Kuppen MCP, et al. Among authors: westgeest hm. Eur Urol Oncol. 2021 Aug;4(4):618-627. doi: 10.1016/j.euo.2019.09.005. Epub 2019 Oct 8. Eur Urol Oncol. 2021. PMID: 31601523
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.
Ismail RK, Suijkerbuijk KPM, de Boer A, van Dartel M, Hilarius DL, Pasmooij AMG, van Zeijl MCT, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil A, Westgeest H, van den Eertwegh AJ, Wouters MWJM. Ismail RK, et al. Melanoma Res. 2022 Dec 1;32(6):460-468. doi: 10.1097/CMR.0000000000000832. Epub 2022 Sep 5. Melanoma Res. 2022. PMID: 35703270 Free PMC article.
Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
Blankenstein SA, Bonenkamp JJ, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Blokx WAM, Boers-Sonderen MJ, van den Eertwegh AJM, Franken MG, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn EW, van Not OJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, van der Veldt AAM, Vreugdenhil G, Westgeest HM, Wouters MWJM, van Akkooi ACJ. Blankenstein SA, et al. Among authors: westgeest hm. Ann Surg Oncol. 2023 Jan;30(1):573-586. doi: 10.1245/s10434-022-12600-2. Epub 2022 Oct 6. Ann Surg Oncol. 2023. PMID: 36203067
Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.
Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, Meiss F, Schlaak M, Schilling B, Westgeest HM, Gutzmer R, Pföhler C, Meier F, Zimmer L, Suijkerbuijk KPM, Haalck T, Thoms KM, Herbschleb K, Leichsenring J, Menzer A, Kopp-Schneider A, Long GV, Kefford R, Enk A, Blank CU, Hassel JC. Menzer C, et al. Among authors: westgeest hm. J Clin Oncol. 2019 Nov 20;37(33):3142-3151. doi: 10.1200/JCO.19.00489. Epub 2019 Oct 3. J Clin Oncol. 2019. PMID: 31580757 Free PMC article.
A clinician's guide for developing a prediction model: a case study using real-world data of patients with castration-resistant prostate cancer.
Veen KM, de Angst IB, Mokhles MM, Westgeest HM, Kuppen M, Groot CAU, Gerritsen WR, Kil PJM, Takkenberg JJM. Veen KM, et al. Among authors: westgeest hm. J Cancer Res Clin Oncol. 2020 Aug;146(8):2067-2075. doi: 10.1007/s00432-020-03286-8. Epub 2020 Jun 17. J Cancer Res Clin Oncol. 2020. PMID: 32556680 Free PMC article. Review.
Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells.
Rijnders M, Balcioglu HE, Robbrecht DGJ, Oostvogels AAM, Wijers R, Aarts MJB, Hamberg P, van Leenders GJLH, Nakauma-González JA, Voortman J, Westgeest HM, Boormans JL, de Wit R, Lolkema MP, van der Veldt AAM, Debets R. Rijnders M, et al. Among authors: westgeest hm. Clin Cancer Res. 2022 Jan 1;28(1):215-226. doi: 10.1158/1078-0432.CCR-20-3319. Epub 2021 Oct 6. Clin Cancer Res. 2022. PMID: 34615720
[No title available]
[No authors listed] [No authors listed] PMID: 36319872
56 results